Genmab’s revenue for the first nine months of 2025 increased by 21% to $2,662 million compared to the same period in 2024. The company announced the proposed acquisition of Merus N.V. and received FDA approvals for Rina-S® in endometrial cancer and epcoritamab in advanced lymphoma. The acquisition is expected to close in early 2026.

The increase in revenue was primarily driven by higher DARZALEX® and Kesimpta® royalties under collaborations with J&J and Novartis. Operating profit for the first nine months of 2025 was $1,007 million, up from $662 million in 2024. Genmab is maintaining its financial guidance for 2025 and aims to accelerate growth through strategic acquisitions and product development.

Genmab’s proposed acquisition of Merus for $8.0 billion will add petosemtamab, a late-stage asset with two BTDs, to its portfolio. The acquisition is funded through cash and debt financing, with a commitment from Morgan Stanley Senior Funding, Inc. Genmab expects to close the transaction by early 2026, subject to customary conditions.

Genmab’s CEO, Jan van de Winkel, highlighted the company’s progress in advancing its late-stage portfolio with FDA approvals and commercial entry into the German market. The company aims to reach more patients with its approved medicines and accelerate growth through strategic acquisitions and product development. Genmab’s conference call to discuss the results for the first nine months of 2025 will be held on November 6.

Read more at GlobeNewswire: Genmab Announces Financial Results for the Nine Months of